- Home
- ARGX
ARGX
argenx SE
as 12-20-2024 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
| Founded: | 2008 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 37.3B | IPO Year: | 2017 |
| Target Price: | $634.50 | AVG Volume (30 days): | 290.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $349.86 - $644.97 | Next Earning Date: | 10-31-2024 |
| Revenue: | $1,908,659,000 | Revenue Growth: | 85.56% |
| Revenue Growth (this year): | 61.99% | Revenue Growth (next year): | 42.48% |
Latest argenx SE News
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
Insider Monkey
10 days ago
Here’s Why argenx SE (ARGX) Surged in Q3
Insider Monkey
13 days ago
Should You Increase Your Holdings in argenx SE (ARGX)?
Simply Wall St.
19 days ago
Three Stocks Estimated To Be Undervalued In December 2024
Simply Wall St.
19 days ago
Spotlight On High Growth Tech Stocks This December 2024
Insider Monkey
19 days ago
Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?
GlobeNewswire
a month ago
argenx to Present at Upcoming Investor Conferences
BioPharma Dive
a month ago
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
MT Newswires
a month ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Compare ARGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.